KRAS Mutation Targeted Therapy: A Patient's Guide
Sotorasib was the first major FDA‑approved KRAS G12C inhibitor for previously treated KRAS G12C‑mutated non‑small cell lung cancer.
This article explains how to interpret a KRAS mutation result, its implications for targeted therapy, and the importance of knowing the exact KRAS variant, tumor type, and co‑mutational context. It reviews approved KRAS G12C inhibitors (sotorasib, adagrasib), emerging agents, clinical‑trial options, and testing strategies, emphasizing that KRAS status alone is insufficient for treatment decisions.
A KRAS mutation drives continuous growth signaling, and the specific KRAS variant determines whether a direct inhibitor is available or if a clinical trial is needed.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
- Scientists build cell line atlas of deadly cancers of the bile ducts and gallbladder
- Cholangiocarcinoma Workup: Laboratory Studies, Imaging Studies, Procedures
- New EASL Clinical Practice Guidelines on extrahepatic cholangiocarcinoma
- An open‑label study of pemigatinib in cholangiocarcinoma: final results from FIGHT‑202